Toxicity profile of antibody-drug conjugates in breast cancer: practical considerationsA. D'Arienzo, Filippo Montemurro, Mario Giuliano et al.|EClinicalMedicine|2023Cited by 90
Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patientsFederica Miglietta, Grazia Arpino, Letizia Pontolillo et al.|The Breast|2024Cited by 9
Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysisRoberto Buonaiuto, Michelino De Laurentiis, Aldo Caltavituro et al.|The Breast|2024Cited by 4
Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER)Carmine De Angelis, Grazia Arpino, Martina Pagliuca et al.|The Oncologist|2025Cited by 0